Potential in vitro anti-periodontopathogenic, anti-Chikungunya activities and in vivo toxicity of Brazilian red propolis

Author(s):Show less -

Sousa Silva, Nagela Bernadelli ; de Souza, Jonathan Henrique ; Santiago, Mariana Brentini ; da Silva Aguiar, Jhennyfer Rodrigues ; Silva Martins, Daniel Oliveira ; da Silva, Rafael Alves ; Santos, Igor de Andrade ; Aldana-Mejia, Jennyfer A. ; Gomes Jardim, Ana Carolina ; Pedroso, Reginaldo dos Santos ; Ambrosio, Sergio Ricardo ; Sola Veneziani, Rodrigo Cassio ; Bastos, Jairo Kenupp ; Pires, Regina Helena ; Gomes Martins, Carlos Henrique

• Document type: Journal article
• Source: SCIENTIFIC REPORTS; v. 12, n. 1, p. 16-pg., 2022-12-07.

Abstract

Bacterial and viral infections are serious public health issue. Therefore, this study aimed to evaluate the antibacterial, antibiofilm and antiviral potential of the Brazilian Red Propolis (BRP) crude hydroalcoholic extract, fractions, and isolated compounds, as well as their in vivo toxicity. The antibacterial activity was evaluated by determining the Minimum Inhibitory Concentration and the antibiofilm activity by determining the Minimum Inhibitory Concentration of Biofilm (MICB50). The viable bacteria count (Log(10) UFC/mL) was also obtained. The antiviral assays were performed by infecting BHK-21 cells with Chikungunya (CHIKV) nanoluc. The toxicity of the BRP was evaluated in the Caenorhabditis elegans animal model. The MIC values for the crude hydroalcoholic extract sample ranged from 3.12 to 100 mu g/mL, while fractions and isolated compounds the MIC values ranged from 1.56 to 400 mu g/mL.The BRP crude hydroalcoholic extract, oblongifolin B, and gutiferone E presented MICB50 values ranging from 1.56 to 100 mu g/mL against monospecies and multispecies biofilms. Neovestitol and vestitol inhibited CHIKV infection by 93.5 and 96.7%, respectively. The tests to evaluate toxicity in C. elegans demonstrated that the BRP was not toxic below the concentrations 750 mu g/mL. The results constitute an alternative approach for treating various infectious diseases. (AU)

• FAPESP's process: 17/04138-8 - Attainment of chemical, analytical, biological, pharmacological and technological studies to fill the gaps on the development of Brazilian propolis sector
• Grantee: Jairo Kenupp Bastos
• Support Opportunities: Research Projects - Thematic Grants